Drug Profile
Dihydroartemisinin - Kunming Pharmaceuticals
Alternative Names: DHA - KunmingLatest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Kunming Pharmaceutical
- Class Antimalarials; Artemisinins; Sesquiterpenes
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Systemic lupus erythematosus
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Systemic-lupus-erythematosus in China (PO, Tablet)
- 11 Jan 2018 Preclinical trials in Systemic lupus erythematosus in China (PO) (NCT03396393) before January 2018
- 11 Jan 2018 Kunming Pharmaceuticals plans a phase II trial for Systemic Lupus Erythematosus (Adjunctive therapy) in China (NCT03396393)